Lomelino-Pinheiro Sara, Margarida Bastos, Lages Adriana de Sousa
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.
Endocrinol Diabetes Metab Case Rep. 2020 May 5;2020. doi: 10.1530/EDM-20-0005.
Familial hypomagnesemia with secondary hypocalcemia (FHSH) is a rare autosomal recessive disorder (OMIM# 602014) characterized by profound hypomagnesemia associated with hypocalcemia. It is caused by mutations in the gene encoding transient receptor potential cation channel member 6 (TRPM6). It usually presents with neurological symptoms in the first months of life. We report a case of a neonate presenting with recurrent seizures and severe hypomagnesemia. The genetic testing revealed a novel variant in the TRPM6 gene. The patient has been treated with high-dose magnesium supplementation, remaining asymptomatic and without neurological sequelae until adulthood. Early diagnosis and treatment are important to prevent irreversible neurological damage.
Loss-of-function mutations of TRPM6 are associated with FHSH. FHSH should be considered in any child with refractory hypocalcemic seizures, especially in cases with serum magnesium levels as low as 0.2 mM. Normocalcemia and relief of clinical symptoms can be assured by administration of high doses of magnesium. Untreated, the disorder may be fatal or may result in irreversible neurological damage.
家族性低镁血症伴继发性低钙血症(FHSH)是一种罕见的常染色体隐性疾病(OMIM编号:602014),其特征为严重的低镁血症并伴有低钙血症。它由编码瞬时受体电位阳离子通道蛋白6(TRPM6)的基因突变引起。通常在生命的最初几个月出现神经症状。我们报告了一例新生儿反复惊厥并伴有严重低镁血症的病例。基因检测发现TRPM6基因存在一种新的变异。该患者接受了高剂量镁补充治疗,直至成年一直无症状且无神经后遗症。早期诊断和治疗对于预防不可逆的神经损伤很重要。
TRPM6功能丧失突变与FHSH相关。任何患有难治性低钙性惊厥的儿童,尤其是血清镁水平低至0.2 mM的病例,都应考虑FHSH。通过给予高剂量镁可确保血钙正常并缓解临床症状。若不治疗,该疾病可能致命或导致不可逆的神经损伤。